Dashboard
Manage Tickers

TGTX TG THERAPEUTICS, INC.

Nasdaq tgtherapeutics.com


$ 33.47 $ -1.10 (-3.18 %)    

Thursday, 23-Oct-2025 18:43:29 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 611.70 $ 5.09 (0.84 %)
DIA $ 467.20 $ 1.51 (0.32 %)
SPY $ 672.21 $ 3.96 (0.59 %)
TLT $ 91.38 $ -0.63 (-0.68 %)
GLD $ 378.90 $ 1.51 (0.4 %)
$ 33.49
$ 34.60
$ 33.42 x 5
$ 34.75 x 20
$ 32.93 - $ 34.81
$ 22.61 - $ 46.48
1,967,645
na
5.31B
$ 1.76
$ 87.89
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-03-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-09-2024 06-30-2024 10-Q
6 05-06-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-06-2023 09-30-2023 10-Q
9 08-04-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-01-2023 12-31-2022 10-K
12 11-09-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-11-2020 03-31-2020 10-Q
23 03-02-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-10-2019 05-10-2019 10-Q
27 03-01-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-15-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-10-2016 03-31-2016 10-Q
39 03-15-2016 12-31-2015 10-K
40 11-09-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

small-cap-biotech-climb-bios-lead-drug-candidate-has-larger-long-term-opportunity
Small-Cap Biotech Climb Bio's Lead Drug Ca...
10/16/2025 17:40:28

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therap...

ihc-wainwright--co-assumes-tg-therapeutics-at-buy-announces-price-target-of-60
IHC Wainwright & Co. Assumes TG Therapeuti...
10/06/2025 10:47:28

HC Wainwright & Co. analyst Emily Bodnar assumes TG Therapeutics (NASDAQ:TGTX) with a Buy rating and announces Price Tar...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/01/2025 17:35:33

tg-therapeutics-reports-near-zero-relapse-rate-after-6-years-of-briumvi-treatment-in-multiple-sclerosis-with-no-new-safety-signals
TG Therapeutics Reports Near-Zero Relapse ...
09/24/2025 13:12:08

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring e...

b-riley-securities-maintains-buy-on-tg-therapeutics-raises-price-target-to-55
B. Riley Securities Maintains Buy on TG Th...
09/17/2025 18:12:00

B. Riley Securities analyst Mayank Mamtani maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target fr...

tg-therapeutics-to-present-long-term-briumvi-data-in-relapsing-ms-at-ectrims-2025-including-six-year-ultimate-i--ii-results-and-real-world-enable-study-updates
TG Therapeutics To Present Long-Term BRIUM...
09/10/2025 11:36:36

tg-therapeutics-to-present-long-term-briumvi-data-in-relapsing-ms-at-ectrims-2025-including-six-year-ultimate-i--ii-results-and-real-world-enable-study-updates
TG Therapeutics To Present Long-Term BRIUM...
09/10/2025 11:33:25

tg-commenced-enrollment-phase-3-trial-for-subcutaneous-briumvi
TG Commenced Enrollment Phase 3 Trial For ...
09/08/2025 11:30:41

tg-therapeutics-ceo-voices-strong-conviction-in-briumvi-with-new-100-million-buyback
TG Therapeutics CEO Voices Strong Convicti...
09/03/2025 16:40:49

TG Therapeutics' stock rose after completing a $100 million buyback and approving another $100 million plan, reinforcing co...

tg-therapeutics-authorizes-new-100m-repurchase-program
TG Therapeutics Authorizes New $100M Repur...
09/03/2025 11:31:56

tg-therapeutics-files-for-mixed-shelf-offering-size-not-disclosed
TG Therapeutics Files For Mixed Shelf Offe...
08/08/2025 21:27:30

-SEC Filing

crude-oil-falls-15-on-semiconductor-shares-plunge-after-q2-results
Crude Oil Falls 1.5%; ON Semiconductor Sha...
08/04/2025 17:33:21

briumvis-strong-sales-cant-stop-tg-therapeutics-stock-slide
Briumvi's Strong Sales Can't Stop TG Thera...
08/04/2025 17:14:25

TG Therapeutics missed Q2 earnings and revenue expectations but raised its 2025 Briumvi sales guidance following strong global ...

tg-therapeutics-raises-fy2025-sales-guidance-from-575000m-to-585000m-vs-596120m-est
TG Therapeutics Raises FY2025 Sales Guidan...
08/04/2025 11:01:26

TG Therapeutics (NASDAQ:TGTX) raises FY2025 sales outlook from $575.000 million to $585.000 million vs $596.120 million estimate.

tg-therapeutics-q2-eps-017-misses-019-estimate-sales-141148m-miss-146422m-estimate
TG Therapeutics Q2 EPS $0.17 Misses $0.19 ...
08/04/2025 11:00:44

TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0....

Core News & Articles
Earnings Scheduled For August 4, 2025
08/04/2025 08:32:29

whats-next-tg-therapeuticss-earnings-preview
What's Next: TG Therapeutics's Earnings Pr...
08/01/2025 19:03:11

cramer-backs-this-mining-giant-after-16b-bet
Cramer Backs This Mining Giant After $1.6B...
07/01/2025 12:11:40

Jim Cramer recommends buying Rio Tinto due to its high yield. TG Therapeutics is also a buy, with strong first-quarter sales an...

tg-therapeutics-presents-data-highlighting-briumvi-in-patients-with-relapsing-forms-of-multiple-sclerosis-at-2025-cmsc-annual-meeting
TG Therapeutics Presents Data Highlighting...
05/30/2025 11:31:31

tg-therapeutics-announces-upcoming-schedule-of-presentations-highlighting-briumvi-data-in-patients-with-rms-at-2025-cmsc-annual-meeting
TG Therapeutics Announces Upcoming Schedul...
05/27/2025 11:37:40

TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION